SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Meituan (MPNGF) , forward earnings yield 37.31%. PEG 0.06 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (90/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.06); analyst target implies upside (+40.8%).
- Forward P/E 2.7
- PEG Ratio 0.06 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $15.00 (+40.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 59/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
90/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MPNGF
Valuation Multiples
P/E (TTM)0.0
Forward P/E2.7
PEG Ratio0.06
Forward PEG0.06
P/B Ratio0.00
P/S Ratio0.18
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.85
Forward EPS (Est.)$3.97
Book Value / Share$0.00
Revenue / Share$58.49
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield37.31%
Dividend Yield0.00%
Analyst Target$15.00 (+40.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.05 |
$12.99B |
$-5.79B |
-44.6% |
| 2017 |
$-3.44 |
$33.93B |
$-18.92B |
-55.8% |
| 2018 |
$-42.40 |
$65.23B |
$-115.48B |
-177% |
| 2019 |
$0.38 |
$97.53B |
$2.24B |
2.3% |
| 2020 |
$0.78 |
$114.79B |
$4.71B |
4.1% |
| 2021 |
$-3.90 |
$179.13B |
$-23.54B |
-13.1% |
| 2022 |
$-1.09 |
$219.95B |
$-6.69B |
-3% |
| 2023 |
$2.20 |
$276.74B |
$13.86B |
5% |
| 2024 |
$0.79 |
$337.59B |
$35.81B |
10.6% |
| 2025 |
$-3.85 |
$355.44B |
$-22.75B |
-6.4% |
